HomeBUSINESS
BUSINESS

Daiichi Sankyo’s ADC DS-8201 Enters Global PII Study for Colorectal Cancer
(Mar.9.2018)

Daiichi Sankyo said on March 8 that the first patients were dosed in a global PII study of its investigational HER2-targeting antibody drug conjugate (ADC) DS-8201 for HER2-expressing advanced colorectal cancer ...
(LOG IN FOR FULL STORY)